Physician profile
Ramkrishna Surendran
NPI 1679507669
$7,395.15
in general payments reported to CMS, 2019-2025
46 companies · $1,318 in 2025
The $1,318 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $718 · 2020: $485 · 2021: $963 · 2022: $1,752 · 2023: $1,315 · 2024: $844 · 2025: $1,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,476.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,289.76 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Glaxosmithkline, LLC. | $724.04 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $601.78 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $531.68 | 2019-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $414.45 | 2019-2025 | |
| Lilly USA, LLC | $384.52 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $299.77 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $243.35 | 2019-2025 | Vpriv |
| Sanofi-Aventis U.S. LLC | $240.12 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $229.38 | 2021-2025 | |
| Amarin Pharma, INC. | $226.24 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $215.86 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Ironwood Pharmaceuticals, INC | $151.25 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $140.29 | 2025 | Fanapt |
| Heartflow, INC. | $132.51 | 2022 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $121.34 | 2025 | Hydropearl, Azur Cx Detachable, Navicross |
| Exact Sciences Corporation | $110.52 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $106.42 | 2021-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $105.36 | 2021-2025 | Id Now Instrument, Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.60 | 2020-2025 | Xifaxan |
| Genzyme Corporation | $84.37 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $81.29 | 2022 | |
| Medtronic Vascular, INC. | $76.79 | 2019 | |
| Alk-Abello, INC | $70.98 | 2024-2025 | Grastek, Odactra, Ragwitek |
| Allergan, INC. | $65.02 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $61.68 | 2022 | |
| Qol Medical, LLC | $58.53 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $51.56 | 2019 | |
| Nestle Healthcare Nutrition INC. | $49.07 | 2021 | |
| Axsome Therapeutics, INC. | $48.93 | 2025 | Auvelity |
| Daiichi Sankyo INC. | $44.83 | 2024-2025 | Injectafer |
| Genentech USA, INC. | $39.21 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $37.81 | 2022-2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.22 | 2022-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $25.06 | 2021-2022 | |
| Organon LLC | $24.05 | 2025 | Nexplanon |
| Inari Medical, INC. | $22.48 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Ani Pharmaceuticals, INC. | $19.67 | 2025 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $19.00 | 2025 | Opsumit, Uptravi |
| Seqirus USA INC | $18.25 | 2025 | Fluad, Flucelvax |
| Owp Pharmaceuticals, INC. | $17.29 | 2022 | |
| Dermira, INC. | $16.94 | 2020 | |
| Xeris Pharmaceuticals, INC. | $16.86 | 2024 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $16.42 | 2021 | |
| Shire North American Group INC | $12.66 | 2019 | |
| Janssen Biotech, INC. | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramkrishna Surendran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.